Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL21403375 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL870938 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL27640995 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL3293375 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL28107748 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL28415027 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL28134059 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL29777539 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL27745349 | 0.96 | LMNA (0.44) | LMNAL3MBTL1TDP1TP53PDE4A | |
| Demannose SCHEMBL27616123 | 0.92 | LMNA (0.41) | LMNAL3MBTL1TDP1TP53PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9332741-B2 | TL1A model of inflammation fibrosis and autoimmunity | CEDARS-SINAI MEDICAL CENTER (US) | 2016-05-10 | — | — | US | claimed |
| US-20150026831-A1 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY | CEDARS-SINAI MEDICAL CENTER (US) | 2015-01-22 | — | — | US | claimed |
| US-8766034-B2 | TL1A model of inflammation fibrosis and autoimmunity | CEDARS-SINAI MEDICAL CENTER (US) | 2014-07-01 | — | — | US | claimed |
| US-20120079611-A1 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY | CEDARS-SINAI MEDICAL CENTER (US) | 2012-03-29 | — | — | US | claimed |
| WO-2025092276-A1 | PULSATILLA SAPONIN B4 DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州大学 | 2025-05-08 | — | — | WO | disclosed |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-116549657-B | Method for promoting endocytosis of animal albumin and application thereof | 中国农业大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-116549657-A | Method for promoting endocytosis of animal albumin and application thereof | 中国农业大学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023104058-A1 | MACROPHAGE-BASED LIVING CELL DRUG-LOADING SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳先进技术研究院 | 2023-06-15 | — | — | WO | disclosed |
| US-9332741-B2 | TL1A model of inflammation fibrosis and autoimmunity | CEDARS-SINAI MEDICAL CENTER (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150026831-A1 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY | CEDARS-SINAI MEDICAL CENTER (US) | 2015-01-22 | — | — | US | disclosed |
| CN-101663321-B | Antagonistic human light-specific human monoclonal antibodies | KYOWA HAKKO KIRIN CO.,LTD. (JP) | 2014-10-08 | — | — | CN | disclosed |
| US-8766034-B2 | TL1A model of inflammation fibrosis and autoimmunity | CEDARS-SINAI MEDICAL CENTER (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120079611-A1 | TL1A MODEL OF INFLAMMATION FIBROSIS AND AUTOIMMUNITY | CEDARS-SINAI MEDICAL CENTER (US) | 2012-03-29 | — | — | US | disclosed |
| CN-101663321-A | Antagonistic human light-specific human monoclonal antibodies | KIRIN PHARMA KK | 2010-03-03 | — | — | CN | disclosed |
| CN-101589060-A | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists | ZYMOGENETICS INC (US) | 2009-11-25 | — | — | CN | disclosed |
| WO-1996041021-A1 | METHOD AND APPARATUS FOR THE RECOVERY AND PURIFICATION OF ORGANIC ACIDS | CHRONOPOL, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0166900-A2 | Polyorganosiloxane-based graft copolymer and process for producing same | MITSUBISHI RAYON CO., LTD. (JP) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | LMNA 385/4885L3MBTL1 792/4885TDP1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.